ULTRAGENYX PHARMACEUTICAL INC. Available-for-sale Securities
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Available-for-sale Securities of $918.63 million as of 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecurities · last filed 2021-11-03
- 2021-09-30: Available-for-sale Securities $918.63M.
- 2021-06-30: Available-for-sale Securities $941.37M.
- 2021-03-31: Available-for-sale Securities $1.02B.
- 2020-12-31: Available-for-sale Securities $1.17B.
| Period end | Available-for-sale Securities |
|---|---|
| 2021-09-30 | $918.63M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $941.37M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $1.02B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.17B 10-Q · filed 2021-11-03 |
| 2020-09-30 | $746.80M 10-Q · filed 2020-10-27 |
| 2020-06-30 | $788.85M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $663.04M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $741.17M 10-K · filed 2021-02-12 |
| 2019-09-30 | $502.88M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $604.34M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $700.01M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $434.74M 10-K · filed 2020-02-14 |
| 2018-09-30 | $482.87M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $540.84M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $528.83M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $223.65M 10-K · filed 2019-02-20 |
| 2017-09-30 | $377.85M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $442.65M 10-Q · filed 2017-07-28 |
| 2017-03-31 | $497.98M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $482.88M 10-K · filed 2018-02-21 |
| 2016-09-30 | $451.03M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $427.34M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $472.91M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $514.34M 10-K · filed 2017-02-17 |
| 2015-09-30 | $570.00M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $307.81M 10-Q · filed 2015-08-14 |
| 2015-03-31 | $328.30M 10-Q · filed 2015-05-12 |
| 2014-12-31 | $175.81M 10-K · filed 2016-02-26 |
| 2014-09-30 | $194.94M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $143.58M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $161.06M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $52.80M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |